SecBot SecBot
6-K ·Filed Aug 4, 2026

SNN

SMITH & NEPHEW PLC
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001104659-26-089991
Notable filing: 6-K
Actionable Insight ▼ Bearish

The revenue guidance cut is the dominant signal here, the profit beat is largely cost-driven and not sustainable if top-line momentum continues to decelerate. Watch Q3 trading report on Nov 6 for confirmation of the H2 step-up in Orthopaedics and Bioactives; if US Knee Implants don't inflect, further downside is likely.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.44
T+0 close · Aug 4, 2026 · via day close
Latest settled
−1.12%
T+60 · $30.10
Vs SPY
−1.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $30.44entry
  2. T+1 · 3mo ago −1.02%α −0.82% · $30.13
  3. T+5 · 3mo ago −1.41%α −1.31% · $30.01
  4. T+20 · 3mo ago −4.83%α −3.59% · $28.97
  5. T+60 · 20d ago −1.12%α −1.49% · $30.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying, +4.6% reported) and Q2 revenue of $1,597M (+1.6% underlying). While trading profit grew 8.1% to $566M and EPSA rose 11.0% to 47.7 cents, the company cut full-year revenue guidance from ~6% to ~4% due to weakness in US Orthopaedics and Advanced Wound Bioactives. The miss on top-line guidance and ongoing structural headwinds in Knee Implants and skin substitutes outweigh the profit beat and $500M buyback, making this a bearish read-through for the stock.

Key Facts

  • Q2 underlying revenue growth of 1.6% missed expectations; full-year revenue guidance cut from ~6% to ~4%
  • H1 trading profit up 8.1% to $566M, driven by $130M in efficiency savings and tariff refunds
  • US Knee Implants declined -7.2% in Q2; US Hip Implants declined -1.5% after four quarters of above-market growth
  • Advanced Wound Bioactives revenue fell -12.7% underlying in Q2 due to skin substitute reimbursement changes
  • Sports Medicine & ENT remained strong with Q2 underlying growth of 8.6%
  • EPSA up 11.0% to 47.7 cents; basic EPS up 6.2% to 35.6 cents
  • Free cash flow was $231M, down 5.2% YoY due to $51M increase in capex
  • Net debt/EBITDA leverage at 1.8x; $500M buyback announced in May with $216M settled as of Aug 3
  • Interim dividend increased 4.0% to 15.6 cents per share
  • FDA granted De Novo classification for TESSA Spatial Surgery System

Financial Impact

Full-year revenue guidance cut from ~6% to ~4% growth; trading profit guidance unchanged at ~$1.3B; free cash flow guidance unchanged at ~$800M

revenuetrading profitfree cash flowEPS

Risk Factors

  • US Orthopaedics recovery may be slower than guided, especially Knee Implants ahead of LANDMARK launch
  • Skin substitute headwind could exceed the upper end of the $20-40M guided range
  • Tariff refunds may not repeat in H2, exposing the P&L to the original tariff headwind
  • China VBP implementation in H2 2026 could pressure Sports Medicine and ENT growth

Market Snapshot

Exchange
OTC
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
50% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-089991
Document: 0001104659-26-089991-index-headers.html0001104659-26-089991
Document: 0001104659-26-089991-index.html0001104659-26-089991
Document: 0001104659-26-089991.txt0001104659-26-089991

Track record

42 reports on SNN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
  2. Nov 4, 202612d ago 6-K Bearish 6/10 No price data
  3. Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
  4. Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
  5. Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
  6. Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
  7. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  8. Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
  9. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
  10. Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
Showing 10 of 42

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026